Skip to main content
Top

Cellular Oncology

Issue 4/2022

Content (12 Articles)

Role of ELMO1 in inflammation and cancer—clinical implications

Stefania Tocci, Stella-Rita Ibeawuchi, Soumita Das, Ibrahim M. Sayed

Open Access Oropharyngeal Cancer Original Article

Application of circulating tumour cells to predict response to treatment in head and neck cancer

Xi Zhang, Chameera Ekanayake Weeramange, Brett G. M. Hughes, Sarju Vasani, Zhen Yu Liu, Majid Ebrahimi Warkiani, Gunter Hartel, Rahul Ladwa, Jean Paul Thiery, Liz Kenny, Chamindie Punyadeera

Choroidal Melanoma Original Article

Inhibition of CD146 lessens uveal melanoma progression through reducing angiogenesis and vasculogenic mimicry

Ronghan Zhang, Xiaogang Chen, Shengwen Chen, Jiajia Tang, Feng Chen, Yong Lin, Peter Sol Reinach, Xiyun Yan, LiLi Tu, Hongxia Duan, Jia Qu, Qiang Hou

Hepatitis B Original Article

Spatiotemporal modulation of SMAD4 by HBx is required for cellular proliferation in hepatitis B-related liver cancer

Wang Chaomin, Niu Wenhao, Hua Jialei, Zhao Ting, Feng Honglei, Hao Zhuang, Wang Yichao, Bai Changsen, Li Yueguo

Open Access Breast Cancer Original Article

Genomic copy number alterations as biomarkers for triple negative pregnancy-associated breast cancer

B. B. M. Suelmann, A. Rademaker, C. van Dooijeweert, E. van der Wall, P. J. van Diest, C. B. Moelans

Open Access Choroidal Melanoma Original Article

The multi-kinase inhibitor afatinib serves as a novel candidate for the treatment of human uveal melanoma

Wenying Shu, Xue Zhu, Ke Wang, Svetlana Cherepanoff, R. Max Conway, Michele C. Madigan, Hong Zhu, Ling Zhu, Michael Murray, Fanfan Zhou

Open Access Metastasis Original Article

EV-miRome-wide profiling uncovers miR-320c for detecting metastatic colorectal cancer and monitoring the therapeutic response

Chan-Keng Yang, Hung-Chih Hsu, Yu-Hao Liu, Wen-Sy Tsai, Chung-Pei Ma, Yi-Tung Chen, Bertrand Chin-Ming Tan, Ying-Yu Lai, Ian Yi-Feng Chang, Chi Yang, Chia-Yu Yang, Jau-Song Yu, Hsuan Liu

Open Access Original Article

Selective targeting BMP2 and 4 in SMAD4 negative esophageal adenocarcinoma inhibits tumor growth and aggressiveness in preclinical models

Shulin Li, Sanne J. M. Hoefnagel, Matthew Read, Sybren Meijer, Mark I. van Berge Henegouwen, Suzanne S. Gisbertz, Elena Bonora, David S. H. Liu, Wayne A. Phillips, Silvia Calpe, Ana C. P. Correia, Maria D. C. Sancho-Serra, Sandro Mattioli, Kausilia K. Krishnadath

Open Access Kidney Cancer Original Article

VHL and DNA damage repair pathway alterations as potential clinical biomarkers for first-line TKIs in metastatic clear cell renal cell carcinomas

Jiale Zhou, Junyun Wang, Wen Kong, Jin Zhang, Xiaorong Wu, Jiwei Huang, Junhua Zheng, Yonghui Chen, Wei Zhai, Wei Xue

Gallbladder Cancer Original Article

Novel protein kinase inhibitor TT-00420 inhibits gallbladder cancer by inhibiting JNK/JUN-mediated signaling pathway

Huijie Miao, Yajun Geng, Yang Li, Shijie Tang, Feiling Feng, Weijian Li, Yongsheng Li, Liguo Liu, Rui Zhang, Shimei Qiu, Ying Wu, Zeyu Wang, Ziyi Wang, Ziyu Shao, Ke Liu, Lu Zou, Mao Yang, Yuhao Zhao, Chen Chen, Zhizhen Li, Dadong Zhang, Peng Peng, Xiaoyan Qiang, Frank Wu, Yongning He, Luonan Chen, Dongxi Xiang, Xiaoqing Jiang, Maolan Li, Yun Liu, Yingbin Liu

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine